Welcome to Dynamic Entropy Technology LLC

Our Business

  • Contract Research & Development Services
  • Technology Development & Transfer
  • Solving Problems Through Sci. & Eng. 
  • Consultant services

Our Founders

  • Dr. Xingguo (Jack) Cheng, Chief Science Officer (CSO)

  • President: Dr. Mark Feng

Our Key Advantages

  • Over 20 Years of Experiences

  • Inventors of multiple U.S. Patents

  • Low indirect cost (<40%)

 

  OUR MISSIONS

  • To develop new technologies in health sciences for better life of human beings through innovations and technology transfer
  • To provide R&D services for government, universities, and industries. 
 

  COMPANY NEWS

  • Secured new domain DeTBio.com
  • Setting up Advisory Board
  • Setting up a new laboratory
  • Dr. Cheng-Reviewer of NIH Grant Review Panel (ZRG1 IDM-V): Infectious Diseases & Microbiology (IDM), Special Emphasis Panel
  • Dr. Cheng-Reviewer of Wound Care-(WC5) Review Panel for Combat Readiness – Medical Research Program (CRRP), CDMRP
  • Dr. Cheng-Reviewer (ad hoc) of Peer-reviewed Medical Research Program (PRMRP) and Peer-reviewed Orthopedics Research Program (PRORP) 

Our Technologies

Drug, gene and vaccine delivery (Formulation)

Biomaterials (polymers, ceramics, proteins, hybrids)

Coating for medical implants

 

Nanoparticles (Au, magnetic, CaP, Polymer, Lipid, etc.)

Delivery substrates from aligned polymer biomaterials for tissue repair        

Liposomes

Bioencapsulation and Nanomedicine

Oral, intranasal, transdermal, intravenous, intramuscular, intracranial, intraosseous delivery 

Antimicrobial product development

Tissue engineering and regeneration

Our Facilities

Chemical Reactors (Batch & Continuous), Furnace, Catalyst Manufacturing, Chromatography, Electrophoresis, Biomaterial /nanoparticle characterization, Microscopies, Emulsions, Lipid Extrusion and sonication, ISO9001:2015, GLP, cGMP, ISO1485 to be certified...

Funding News 

  • September 2019, Dynamic Entropy Technology (DetBio LLC) collaborated with Dr. Jian Yang at Penn. State University (PSU) and received a Phase-I small business technology transfer (STTR) award ($225,000) from NIH-NIDDK. The project is mainly based on transfer of the novel PSU antibacterial/antifungal citrate-based polymer technology as medical devices for diabetic skin infections. See Disclaimer

  • With commercial clients' support, DetBio will work with USDA, FDA and EPA for regulatory approval of drug/antimicrobial products (pesticides, sanitizer, disinfectant...) 

  • 2019 SBIR/STTR proposal submission: DetBio is transfering several technologies from Universities/Institutes such as PSU, Cornell University, Texas A&M, Texas Biomed. Research Inst, UTSA, Saint Luis Uni., Saint Luis Va Medical Center, etc.  

  • Dr. Cheng was a subaward PI ($200K) of an awarded NIH R01 Universal Nano Vaccine Partnership grant (PI: Balaji Narasimhan, total 5.6 million $). The subaward, however, will stay with his previous employer, SwRI.

  • Dr. Cheng, Principal Investigator, was awarded a small business technology transfer (STTR) award (total award $150K) from the Defense Health Agency in 2018. The topic is related to intranasal, targeted nanoparticle drug delivery for traumatic brain injury (TBI). The to-be-developed technology can also be applied for treatment of many other neural diseases such as Parkinson's disease, Alzheimer's disease, Brain tumors, etc. 

 

Contact Us

(for collaboration and solve your problems )

Customer Service: 

Jack Cheng or Mark Feng

4923 Kenton Lake

San Antonio, TX 78240-5404

xchengswri@gmail.com

xchengswri@dynamicentropy.com

dynamicentropyllc@gmail.com

T: 216-269-6757 or 210-248-4440

F: 210-561-4303

Laboratory address: 002 Granburg Rd, Lyte, Texas, 78052